This paper aims to provide a review and synthesis of the performance-based contracting
(PBC) literature across academic disciplines. It also seeks to examine how the operations …

Background There has been an increase in'risk sharing'schemes for pharmaceuticals
between healthcare institutions and pharmaceutical companies in Europe in recent years as …

There is a significant and growing interest among both payers and producers of medical
products for agreements that involve a “pay-for-performance” or “risk-sharing” element …

Abstract Background Managed entry agreements (MEAs) are a set of instruments to facilitate
access to new medicines. This study surveyed the implementation of MEAs in Central and …

Managed entry agreements are a set of instruments used to reduce the impact of uncertainty
and high prices when introducing new medicines. This study develops a conceptual …

In recent years policy-makers in European countries have been increasingly concerned
about developments in the pharmaceutical sector that have been challenging the …

Background Until recently, purchasers' options regarding whether to pay for the use of
medical technologies have been binary in nature: a treatment is either covered or not …

The UK Government is proposing a novel form of price regulation for branded medicines,
which it has dubbed 'value-based pricing'(VBP). The specifics of how VBP will work are …

Risk-sharing agreements, under which payers and pharmaceutical manufacturers agree to
link payment for drugs to health outcomes achieved, rather than the volume of products …

Objective The aim of this review is to provide a summary of the literature on risk-sharing
agreements, including conceptual, theoretical and empirical (number of agreements and …